Skip to main content

Table 3 Clinical and demographic characteristics of patients with and without clinical cure

From: Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa

  Clinical cure Clinical failure P-value
(n = 72) (n = 19)
Male sex 49 (68) 17 (89.5) 0.06
Age, years* 66.5 (24–88) 67 (41–84) 0.59
APACHE II* 11 (2–28) 13.5 (6–24) 0.05
Co-morbidities, n (%):
 Malignancy 11 (15.3) 3 (15.8) 1
 Cardiovascular 21 (29.2) 5 (26.3) 1
 Pulmonary 24 (33.3) 9 (47,4) 0,26
 Diabetes Mellitus 20 (27.8) 1 (5.3) 0.06
 Urogenitala 11 (15.3) 3 (15.8) 1
 Hepatic 8 (11.1) 8 (0) 0.2
 Haematologicalb 9 (12.5) 3 (15.8) 0.7
 Neurologicalc 16 (22.2) 2 (10.5) 0.34
Charlson* 4.5 (0–10) 4 (1–9) 0.73
McCabe** 1.4 ± 0.6 1.7 ± 0.7 0.11
Severe sepsis, n (%) 49 (68.1) 9 (47.4) 0.095
Shock 6 (8.3) 1 (5.3) 0.65
Patients with CKD at baseline 16 (22.2) 3 (15.8) 0.53
Department of hospitalization:
 Medical 38 (52.8) 6 (31.6) 0.16
 Surgical 23 (32) 9 (47.4)  
 ICU2 11 (15.3) 4 (21.1)  
Admission diagnosis category:
 Infection 19 (26.4) 7 (36.8)  
 Other-medical 30 (41.7) 5 (26.3)  
 Other-surgical 23 (3.9) 7 (36.8) 0.45
CMS daily dose (millions IU)** 5.3 ± 2.3 6.2 ± 2.1 0.094
CMS total dose (millions IU)** 105.91 ± 88.9 141.2 ± 129.5 0.45
CMS duration of treatment, days** 20.66 ± 16.1 22.6 ± 18.5 0.81
Combined treatment, n (%) 35 (48.6) 11 (57.9) 0.47
Css (mg/mL)** 1.49 ± 1.4 2.42 ± 1.49 0.01
Css > 1.25 (mg/mL), n (%) 32 (45.1) 14 (73.7) 0.027
Css/MIC** 3.13 ± 2.9 4.61 ± 2.86 0.03
AKI at day 7, n (%) 18 (25) 12 (63.2) 0.002
AKI at the EOT, n (%) 33 (45.8) 16 (84.2) 0.003
Length of stay, days** 69.16 ± 59.5 70.8 ± 39.1 0.19
  1. 1 CKD chronic kidney disease, 2 ICU intensive cure unit, 3 CMS colistin methanesulphonate, 4 IU international units, 5 C ss colistin plasma concentration at steady-state, 6 MIC minimal inhibitory concentration, 7 AKI acute kidney injury, 8 EOT end of treatment
  2. *median (range)
  3. **mean ± SD
  4. aAmong urogenital co-morbidities were, renal disease, kidney stones and obstructive uropathy
  5. bAmong haematological co-morbidities were haemopoietic and lymphoreticular malignances
  6. cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia gravis, sclerosis and any kind of dementia